Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel anticancer drug discovery.

J K Buolamwini1

  • 1Department of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, MS 38677, USA. mcjkb@olemiss.edu

Current Opinion in Chemical Biology
|July 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction.

American journal of physiology. Heart and circulatory physiology·2007
Same author

Antisense anticancer oligonucleotide therapeutics.

Current cancer drug targets·2002
Same author

Cell cycle molecular targets in novel anticancer drug discovery.

Current pharmaceutical design·2000
Same author

Molecular targets in cancer drug discovery: cell-based profiling.

Current pharmaceutical design·2000
Same author

A protein expression database for the molecular pharmacology of cancer.

Electrophoresis·1997
Same author

An information-intensive approach to the molecular pharmacology of cancer.

Science (New York, N.Y.)·1997

Researchers are developing novel anticancer drugs targeting specific molecules to reduce chemotherapy side effects. These targeted therapies focus on cancer cell proliferation, angiogenesis, and metastasis, showing promise in preclinical studies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Conventional chemotherapy causes cytotoxic side effects.
  • Novel molecular targets specific to cancer cells offer a promising alternative.
  • Targeted therapies aim to spare normal cells while eliminating cancer cells.

Purpose of the Study:

  • To review novel molecular targets for selective anticancer drug development.
  • To discuss the role of these targets in tumor biology (proliferation, angiogenesis, metastasis).
  • To highlight advances in targeting specific pathways and proteins in cancer.

Main Methods:

  • Review of preclinical and clinical data on novel anticancer agents.
  • Identification and categorization of molecular targets involved in cancer progression.

Related Experiment Videos

  • Analysis of targets including growth factor receptors, kinases, GTP-binding proteins, and cell adhesion molecules.

    • Main Results:

    • Several novel targets are being investigated, including growth factor receptor tyrosine kinases (EGFR, HER-2/neu), VEGF/bFGF receptors, Ras pathway proteins, protein kinase C, and cyclin-dependent kinases.
    • Targets involved in angiogenesis and metastasis, such as matrix metalloproteinases and angiogenin, are also discussed.
    • Emerging targets include platelet-derived growth factor receptor, MAPK pathway components, integrins, anti-apoptosis proteins (Bcl-2, MDM2, survivin), and telomerase.

    Conclusions:

    • Significant optimism exists for developing selective anticancer drugs with reduced side effects.
    • Targeted therapies offer a new paradigm in cancer treatment by focusing on cancer-specific molecular pathways.
    • Continued research into these novel targets holds potential for improved cancer patient outcomes.